Carregant...
Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics
BACKGROUND: Although major improvements have been made in surgical management, chemotherapeutic, and radiotherapeutic of prostate cancer, many prostate cancers remain refractory to treatment with standard agents. Therefore, the identification of new molecular targets in cancer progression and develo...
Guardat en:
| Publicat a: | J Exp Clin Cancer Res |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5568197/ https://ncbi.nlm.nih.gov/pubmed/28830537 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-017-0583-4 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|